OGX-427 in Castration Resistant Prostate Cancer Patients

Clinical Trial ID NCT01120470

PubWeight™ 71.10‹?›

🔗 Visit the ClinicalTrials.gov page for NCT01120470

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011 27.58
2 Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012 20.79
3 Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010 19.74
4 Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008 18.54
5 Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2012 15.69
6 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006 11.26
7 Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 1999 9.22
8 New strategies in metastatic prostate cancer: targeting the androgen receptor signaling pathway. Clin Cancer Res 2011 2.01
9 Targeting the androgen receptor pathway in castration-resistant prostate cancer: progresses and prospects. Oncogene 2014 1.31
10 Suppression of heat shock protein 27 using OGX-427 induces endoplasmic reticulum stress and potentiates heat shock protein 90 inhibitors to delay castrate-resistant prostate cancer. Eur Urol 2013 0.98
11 A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel. Ann Oncol 2015 0.91
12 Targeting the androgen receptor in prostate and breast cancer: several new agents in development. Endocr Relat Cancer 2015 0.89
13 Recent progress in pharmaceutical therapies for castration-resistant prostate cancer. Int J Mol Sci 2013 0.88
14 Cotargeting stress-activated Hsp27 and autophagy as a combinatorial strategy to amplify endoplasmic reticular stress in prostate cancer. Mol Cancer Ther 2012 0.87
15 Silencing Hsp25/Hsp27 gene expression augments proteasome activity and increases CD8+ T-cell-mediated tumor killing and memory responses. Cancer Prev Res (Phila) 2011 0.86
16 Heat shock protein 27 regulates human prostate cancer cell motility and metastatic progression. Oncotarget 2014 0.83
17 Therapeutic Rationales, Progresses, Failures, and Future Directions for Advanced Prostate Cancer. Int J Biol Sci 2016 0.81
18 RNA therapeutics: RNAi and antisense mechanisms and clinical applications. Postdoc J 2016 0.78
Next 100